A recent study published in Quaternary Research describes the discovery and identification of possible aardvark tracks and ...

We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where ...

We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are ...

Investment analysts at Bank of America began coverage on shares of Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) in a note issued to investors on Monday, MarketBeat reports. The firm set a ...

RBC Capital analyst Brian Abrahams initiated coverage of Aardvark Therapeutics (AARD) with an Outperform rating and $21 price target Aardvark ...

BofA initiated coverage of Aardvark Therapeutics (AARD) with a Buy rating and $22 price target The company’s lead drug ARD-101 is in Phase 3 ...

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...